-
established Samsung Bioepis, a
biosimilar medicine developer, as a
joint venture with Biogen. The
company acquired full
ownership of
Samsung Bioepis in 2022 by...
- GlobeNewswire. "FDA
Approves Samsung Bioepis Ospomyv,
Xbryk (denosumab-dssb), a
Biosimilar to
Prolia and Xgeva".
Samsung Bioepis (Press release). 16 February...
- gain 49.9%
share in
Samsung Bioepis". Healthcareglobal.com. Healthcare.
Retrieved 2 June 2021. "Biogen Idec and
Samsung Bioepis Ink
Biosimilar Deal". Mary...
- 2012,
Biogen formalized a
joint venture with Samsung,
creating Samsung Bioepis. This
joint venture brings Biogen's
expertise and
capabilities in protein...
-
disease in adults. The
applicant for this
medicinal product is
Samsung Bioepis NL B.V.
Pyzchiva is a
biosimilar medicinal product.
Pyzchiva was authorized...
- "FDA
Approves Samsung Bioepis'
Epysqli (eculizumab-aagh) as a
Biosimilar to
Soliris (eculizumab)" (Press release).
Samsung Bioepis. 22 July 2024. Retrieved...
-
April 15, 2011.
Archived from the
original on 2012-07-08. "Merck,
Samsung Bioepis Launch Remicade Biosimilar in U.S." genengnews.com. July 24, 2017. "HIGHLIGHTS...
- the
European Commission authorized Ontruzant, a
biosimilar from
Samsung Bioepis Co., Ltd, for the
treatment of
early breast cancer,
metastatic breast cancer...
-
Inflectra (infliximab-dyyb) in
April 2016. The FDA
approved Samsung Bioepis Co., Ltd.'s
Renflexis (infliximab-abda) in
April 2017.
Biogen released...
- 2023.
Retrieved 4 July 2023.
Wingrove P (1 July 2023). "Organon,
Samsung Bioepis launch copycat for
arthritis drug
Humira at 85% discount". Reuters. Archived...
